News

Six months of Calliditas Therapeutics‘ investigational therapy setanaxib safely and significantly reduced signs of liver damage in people with hard-to-treat primary biliary cholangitis…

Seven new ABCB11 gene mutations were identified as the likely cause of progressive familial intrahepatic cholestasis (PFIC2), according to a study that analyzed the…

Dosing has begun in a Phase 2 clinical trial evaluating the safety and efficacy of DD01 in people with one of two forms of fatty…

A six-month-old baby with Alagille syndrome showed atypical biliary tract abnormalities, including a narrower main bile duct and a gallbladder with a corkscrew-like shape,…

A two-month regimen of Atea Pharmaceuticals’ once-daily oral antiviral treatment for hepatitis C — a combination of bemnifosbuvir and ruzasvir — leads to sustained…

Specialty pharmacy services for Livdelzi (seladelpar), the newly approved second-line therapy for adults with primary biliary cholangitis (PBC), will be provided in the U.S.

Intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver disease, is significantly linked to higher rates of several maternal, fetal, and newborn issues…

Three Phase 3 clinical trials testing Akero Therapeutics‘ experimental injection therapy efruxifermin in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated…

AX-0810, an experimental therapy for biliary atresia and other cholestatic diseases, is expected to enter clinical testing by early next year, according to developer…

Most people with chronic hepatitis B enrolled in a Phase 2b clinical trial were eligible to discontinue their use of standard antiviral medication six…